DOCSLIB.ORG

Xanthine Oxidase Inhibitor Step Therapy with Quantity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Xanthine Oxidase Inhibitor Step Therapy with Quantity Xanthine Oxidase Inhibitor Step Therapy with Quantity Limit Criteria Program Summary This step therapy applies to Commercial and Health Insurance Marketplace formularies only. Quantity limits apply to all formularies. This program is implemented with grandfathering. OBJECTIVE The intent of the step therapy criteria for Xanthine Oxidase Inhibitor is to encourage the use of cost-effective generic allopurinol 300 mg before brand agents and to accommodate for use of brand agents when allopurinol cannot be used due to documented intolerance, FDA labeled contraindication, or hypersensitivity. This step therapy program will require use of the 300 mg allopurinol tablet because clinical literature shows that most patients with moderate gout require 400 mg to 600 mg/day to lower serum uric acid below 6.0 mg/dL. The program allows continuation of therapy when there is documentation that the patient is receiving the requested agent. Requests for brand agents will be reviewed when patient-specific documentation has been provided. TARGET DRUG Uloric (febuxostat) PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Xanthine Oxidase Inhibitor will be approved when ANY ONE of the following is met: 1. The patient’s medication history includes use of allopurinol 300 mg in the past 90 days OR 2. There is documentation that the patient is currently using the requested agent OR 3. The prescriber states the patient is currently using the requested agent AND is at risk if therapy is changed OR 4. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to allopurinol 300 mg Length of approval: 12 months NOTE: If Quantity Limit program also applies, please refer to Quantity Limit documents. AL_PS_Xanthine Oxidase Inhibitor_ST_QL_ProgSum_AR0116_r0416 Page 1 of 4 © Copyright Prime Therapeutics LLC. 04/2016 All Rights Reserved Drug Indication1 Dosage Uloric® Febuxostat is indicated Febuxostat starting (febuxostat) for the chronic dose is 40 mg once management of daily. tablets hyperuricemia in For patients who do not 40 mg & 80 mg patients with gout. achieve serum uric acid Uloric is not (sUA) < 6 mg/dL after recommended for the two weeks of treatment, treatment of 80 mg is recommended asymptomatic once daily. hyperuricemia. For those who have achieved sUA < 6 mg/dL, 40 mg once daily is the recommended dosage. CLINICAL RATIONALE Guidelines The goals of gout treatment are threefold: treating acute inflammation, preventing flares, and lowering serum urate levels. The goal of therapy with urate-lowering drugs is to reduce the serum urate level to <6.0 mg/dL, noting that some patients may need lowering to <5.0 mg/dL to durably improve signs and symptoms of gout.2,10 Monitoring of serum urate is recommended every 2-5 weeks during urate lowering therapy titration, and every 6 months once serum urate target is achieved.2 The Evidence, Expertise, Exchange Initiative (3E) (2014) provided multinational evidence-based recommendations for management of gout, integrating systematic literature review and expert opinion of a broad panel of rheumatologists. There was strong consensus that allopurinol constitutes first line urate lowering therapy after consideration of its safety, efficacy and cost. Uricosurics and low to medium doses of febuxostat are considered alternatives in the presence of intolerance or nonresponsiveness to allopurinol.14 The American College of Rheumatology (ACR) 2012 Guidelines for the Management of Gout2,3 recommend diet and lifestyle measures for the majority of patients with gout. In addition, these pharmacologic therapies are recommended:2 Xanthine oxidase inhibitors allopurinol and febuxostat are first line agents for pharmacologic urate lowering therapy. The ACR did not preferentially recommend either xanthine oxidase inhibitor, but they did note there was a lack of published safety data for febuxostat in the setting of severe chronic kidney disease (CKD). Probenecid was recommended as an alternative to a xanthine oxidase inhibitor in the setting of contraindication or intolerance to ≥ 1 xanthine oxidase inhibitor. Also, probenecid is not recommended for monotherapy in those with a creatinine clearance of < 50 mL/minute. For refractory gout, febuxostat can be substituted for allopurinol in the event of drug intolerance or adverse events. Effective therapeutic options include addition of a uricosuric agent such as probenecid to a xanthine oxidase inhibitor for refractory gout. Pegloticase is appropriate for patients with severe gout disease burden and refractoriness to, or intolerance of, conventional and appropriately dosed urate lowering therapy. Pegloticase is not recommended as first line urate lowering therapy for any case scenarios. AL_PS_Xanthine Oxidase Inhibitor_ST_QL_ProgSum_AR0116_r0416 Page 2 of 4 © Copyright Prime Therapeutics LLC. 04/2016 All Rights Reserved Allopurinol is the first-line therapy for most patients and has been the mainstay of prophylactic treatment for gout and conditions associated with hyperuricemia for over 40 years. 2,4,10 Allopurinol is effective in most patients with hyperuricemia if a sufficient dose is taken, but achieving normal serum urate levels may be difficult in patients with impaired renal function or in transplant recipients.9 Febuxostat is considered an alternative to allopurinol.13 Clinical data supporting the dose escalation of allopurinol from 300 mg daily to 300 mg twice daily measured the percentage of patients who achieved a serum uric acid level of ≤ 5 mg/dL. Dose escalation increased the response rate from 26% (for 300 mg daily) to 78% (for 300 mg twice daily).4 Two large observational studies (one in heart failure and one in hyperuricemic patients) have shown that allopurinol is associated with reduced total mortality.5,6 Two small randomized controlled trials showed allopurinol reduced cardiovascular events markedly in both studies.7,8 The ACR states that the recommended initial dose of allopurinol should not exceed 100 mg/day and should be less for patients with moderate to severe chronic kidney disease (50mg/day).2 The rationale for starting the initial dose at ≤ 100 mg/day is that “a low dose could reduce early gout flares after urate lowering therapy initiation, and as a component risk management with respect to the potential for severe hypersensitivity reaction to allopurinol.”2 Febuxostat Efficacy Two of the pivotal trials submitted to the FDA for approval of febuxostat (FACT, APEX) studied the efficacy of different doses of febuxostat versus placebo and allopurinol in the treatment of hyperuricemia in patients with gout.10,11 Patients had been randomized within these two clinical trials to receive placebo or once-daily febuxostat at a dose of 80 mg, 120 mg, or 240 mg, or once-daily allopurinol at 100 mg, 200 mg, or 300 mg. For gout flare prophylaxis during the first 8 weeks of these trials, patients received naproxen 250 mg twice daily or colchicines 0.6 mg once daily. Primary endpoints were the proportion of patients with sAU levels less than 6.0 mg/dL both at their last three visits and at their final visit. None of the patients in the placebo group satisfied the specified endpoints for sUA <6.0 mg/dL. In the allopurinol 200 mg/d treatment group, for the last three patient visits and at the final patient visit, respectively, these endpoints were satisfied for a significantly greater proportion over the placebo group, at 46% and 66% (P ≤.01 for both).10 Febuxostat treatment satisfied the two endpoints by significantly greater proportions of patients than seen with placebo and with allopurinol at all doses (febuxostat 80 mg, 72%, 94%; febuxostat 120 mg, 78%, 89%; febuxostat 240 mg, 77%, 100%; P ≤ 0.01 in all cases) CONFIRMS, the largest, pivotal, phase 3 clinical trial, showed that febuxostat 80 mg was superior to febuxostat 40 mg and allopurinol 300/200 mg at achieving the main study outcome of serum uric acid less than 6.0 mg/dL at the final visit (67%, 47%, and 42%, respectively; P < .001 for both comparisons).12 It should be noted that clinical trials comparing febuxostat with allopurinol included doses of allopurinol up to 300 mg/day maximum. Evidence has demonstrated that 50% of patients with hyperuricemia and gout require higher doses of allopurinol to achieve the required serum uric acid <6 mg/dL.12 Febuxostat Safety Febuxostat is contraindicated in patients being treated with azathioprine, mercaptopurine or theophylline.10 The most common adverse event leading to discontinuation from therapy with febuxostat was liver function abnormalities in 1.8% of the patients treated with the 40 mg dose and 1.2% of those treated with the 80 mg dose.10 Unlike allopurinol, febuxostat can be AL_PS_Xanthine Oxidase Inhibitor_ST_QL_ProgSum_AR0116_r0416 Page 3 of 4 © Copyright Prime Therapeutics LLC. 04/2016 All Rights Reserved administered to patients with mild to moderate renal insufficiency without need for dose reduction.1 REFERENCES 1. Uloric Prescribing Information. Takeda Pharmaceuticals America, Inc, Deerfield, Il. November 2013. 2. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for the management of gout part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Res. 2012;64(10):1431-1446. 3. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology Guidelines for the management of gout part 2: Therapy and antiinflammatory prophylaxis of gouty arthritis. Arthritis Care & Res. 2012;64(10):1447-1461. 4. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006; 81:925–934 5. Luk AJ, Levin GP, Moore EE, Allopurinol and mortality in hyperuricaemic patients Rheumatology. 2009;48:804-806. 6. Thanassoulis G, Brophy JM, Hugues R, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170(15):1358-1364. 7. Rentoukas E, Tsarouhas K, Tsitsimpikou C, et al. The prognostic impact of allopurinol in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Int J Cardiol. 2010;145:257–258.
Load more

Recommended publications
  • Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics
    Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics Jamelle M. Simmons Dissertation submitted to the Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Engineering Yong W. Lee, Chair Luke E. Achenie Hampton C. Gabler Alexei Morozov Aaron S. Goldstein John H. Rossmeisl November 27, 2018 Blacksburg, Virginia Keywords: Autism Spectrum Disorder, Xanthine Oxidase, Reactive Oxygen Species, Pharmacokinetics, Animal Behavior Copyright 2019, Jamelle M. Simmons Effects of Febuxostat on Autistic Behaviors and Computational Investigations of Diffusion and Pharmacokinetics Jamelle M. Simmons (ABSTRACT) Autism spectrum disorder (ASD) is a lifelong disability that has seen a rise in prevalence from 1 in 150 children to 1 in 59 between 2000 and 2014. Patients show behavioral ab- normalities in the areas of social interaction, communication, and restrictive and repetitive behaviors. As of now, the exact cause of ASD is unknown and literature points to multiple causes. The work contained within this dissertation explored the reduction of oxidative stress in brain tissue induced by xanthine oxidase (XO). Febuxostat is a new FDA approved XO- inhibitor that has been shown to be more selective and potent than allopurinol in patients with gout.The first study developed a computational model to calculate an effective diffu- sion constant (Deff ) of lipophilic compounds, such as febuxostat, that can cross endothelial cells of the blood-brain barrier (BBB) by the transcellular pathway. In the second study, male juvenile autistic (BTBR) mice were treated with febuxostat for seven days followed by behavioral testing and quantification of oxidative stress in brain tissue compared to controls.
    [Show full text]
  • ULORIC Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------WARNINGS AND PRECAUTIONS-------------------­ These highlights do not include all the information needed to use ULORIC safely and effectively. See full prescribing • Cardiovascular Death: In a CV outcomes study, there was a higher information for ULORIC. rate of CV death in patients treated with ULORIC compared to allopurinol; in the same study ULORIC was non-inferior to ULORIC (febuxostat) tablets, for oral use allopurinol for the primary endpoint of major adverse Initial U.S. Approval: 2009 cardiovascular events (MACE). Consider the risks and benefits of WARNING: CARDIOVASCULAR DEATH ULORIC when deciding to prescribe or continue patients on See full prescribing information for complete boxed warning. ULORIC. (1, 5.1) • Gout patients with established cardiovascular (CV) disease • Gout Flares: An increase in gout flares is frequently observed treated with ULORIC had a higher rate of CV death compared to during initiation of anti-hyperuricemic agents, including ULORIC. If those treated with allopurinol in a CV outcomes study. (5.1) a gout flare occurs during treatment, ULORIC need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti- • Consider the risks and benefits of ULORIC when deciding to inflammatory drug [NSAID] or colchicine upon initiation of prescribe or continue patients on ULORIC. ULORIC should only treatment) may be beneficial for up to six months. (2.4, 5.2) be used in patients who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to • Hepatic Effects: Postmarketing reports of hepatic failure, allopurinol, or for whom treatment with allopurinol is not sometimes fatal. Causality cannot be excluded.
    [Show full text]
  • Gouric Insert Final
    Dosage Recommendations in Patients with Renal Impairment and Hepatic are at risk for severe drug-induced liver injury and should not be restarted on febuxostat. Impairment For patients with lesser elevations of serum ALT or bilirubin and with an alternate USE IN SPECIAL POPULATIONS No dose adjustment is necessary when administering Gouric in patients with mild or probable cause, treatment with febuxostat can be used with caution. moderate renal impairment. Pregnancy The recommended dosage of Gouric is limited to 40 mg once daily in patients with severe Thyroid disorders US FDA Pregnancy Category C. There are no adequate and well-controlled studies in renal impairment. Increased TSH values (>5.5 μIU/mL) were observed in patients on long-term treatment pregnant women. Febuxostat should be used during pregnancy only if the potential No dose adjustment is necessary in patients with mild to moderate hepatic impairment. with febuxostat (5.5%) in the long term open label extension studies. Caution is required benefit justifies the potential risk to the fetus. when febuxostat is used in patients with altered of thyroid function. Uric Acid Level Nursing mother COMPOSITION Testing for the target serum uric acid level of less than 6 mg/dL may be performed as early Effects on ability to drive and use machines Febuxostat is excreted in the milk of rats. It is not known whether this drug is excreted in Gouric® 40mg Tablet as two weeks after initiating Gouric therapy. Somnolence, dizziness, paraesthesia and blurred vision have been reported with the use of human milk. Because many drugs are excreted in human milk, caution should be Each film-coated tablet contains: Febuxostat.
    [Show full text]
  • Caffeine in the Treatment of Pain
    Rev Bras Anestesiol ARTIGOS DE REVISÃO 2012; 62: 3: 387-401 ARTIGOS DE REVISÃO Cafeína para o Tratamento de Dor Cristiane Tavares, TSA 1, Rioko Kimiko Sakata, TSA 2 Resumo: Tavares C, Sakata RK – Cafeína para o Tratamento de Dor. Justificativa e objetivos: A cafeína é uma substância amplamente consumida com efeitos em diversos sistemas e que apresenta farmacoci- nética e farmacodinâmica características, causando interações com diversos medicamentos. O objetivo deste estudo é fazer uma revisão sobre os efeitos da cafeína. Conteúdo: Nesta revisão, são abordados a farmacologia da cafeína, os mecanismos de ação, as indicações, as contraindicações, as doses, as interações e os efeitos adversos. Conclusões: Faltam estudos controlados, randomizados e duplos-cegos para avaliar a eficácia analgésica da cafeína nas diversas síndromes dolorosas. Em pacientes com dor crônica, é necessário ter cautela em relação ao desenvolvimento de tolerância, abstinência e interação medi- camentosa no uso crônico de cafeína. Unitermos: ANALGESIA; DOR; DROGAS, Alcaloide/cafeína. ©2012 Elsevier Editora Ltda. Todos os direitos reservados. INTRODUÇÃO Estrutura química A cafeína foi isolada em 1820, mas a estrutura correta des- A cafeína é um alcaloide presente em mais de 60 espécies ta metilxantina foi estabelecida na última década do século de plantas 4. Sua estrutura molecular pertence a um grupo XIX. Os efeitos não foram claramente reconhecidos até 1981, de xantinas trimetiladas que incluem seus compostos inti- quando o bloqueio de receptores adenosina foi correlacio- mamente relacionados: teobromina (presente no cacau) e nado às propriedades estimulantes da cafeína e de seus teofilina (presente no chá) 1. Quimicamente, esses alcaloides análogos 1. Provavelmente a cafeína é uma das substâncias são semelhantes a purinas, xantinas e ácido úrico, que são psicoativas mais utilizadas no mundo, promovendo efeitos compostos metabolicamente importantes 4.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0059868 A1 Miner Et Al
    US 2013 0059868A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0059868 A1 Miner et al. (43) Pub. Date: Mar. 7, 2013 (54) TREATMENT OF GOUT Publication Classification (75) Inventors: Jeffrey Miner, San Diego, CA (US); Jean-Luc Girardet, San Diego, CA (51) Int. Cl. (US); Barry D. Quart, Encinitas, CA A613 L/496 (2006.01) (US) A6IP 29/00 (2006.01) (73) Assignee: Ardea Biociences, Inc., San Diego, CA A6IP 9/06 (2006.01) (US) A613 L/426 (2006.01) A 6LX3/59 (2006.01) (21) Appl. No.: 13/637,343 (52) U.S. Cl. ...................... 514/262.1: 514/384: 514/365 (22) PCT Fled: Mar. 29, 2011 (86) PCT NO.: PCT/US11A3O364 (57) ABSTRACT S371 (c)(1), (2), (4) Date: Oct. 24, 2012 Sodium 2-(5-bromo-4-(4-cyclopropyl-naphthalen-1-yl)-4H Related U.S. Application Data 1,2,4-triazol-3-ylthio)acetate is described. In addition, phar (60) Provisional application No. 61/319,014, filed on Mar. maceutical compositions and uses Such compositions for the 30, 2010. treatment of a variety of diseases and conditions. Patent Application Publication Mar. 7, 2013 Sheet 1 of 10 US 2013/00598.68A1 FIGURE 1 S. C SOC 55000 40 S. s 3. s Patent Application Publication Mar. 7, 2013 Sheet 2 of 10 US 2013/00598.68A1 ~~~::CC©>???>©><!--->?©><??--~~~~~·%~~}--~~~~~~~~*~~~~~~~~·;--~~~~~~~~~;~~~~~~~~~~}--~~~~~~~~*~~~~~~~~;·~~~~~ |×.> |||—||--~~~~ ¿*|¡ MSU No IL-1ra MSU50 IL-1ra MSU 100 IL-1ra MSU500 IL-1ra cells Only No IL-1 ra Patent Application Publication Mar. 7, 2013 Sheet 3 of 10 US 2013/00598.68A1 FIGURE 3 A: 50000 40000 R 30000 2 20000 10000 O -7 -6 -5 -4 -3 Lesinurad (log)M B: Lesinurad (log)M Patent Application Publication Mar.
    [Show full text]
  • Azathioprine-Induced Severe Anemia Potentiated by the Concurrent Use Of
    PRACTICE | CASES CPD Azathioprine-induced severe anemia potentiated by the concurrent use of allopurinol Lorenzo Madrazo MD, Emily Jones MD, Cyrus C. Hsia MD n Cite as: CMAJ 2021 January 18;193:E94-7. doi: 10.1503/cmaj.201022 66-year-old man presented to the emergency depart- ment with a 2-week history of progressive weakness and KEY POINTS lethargy. Three months before presentation, he had • Severe anemia and myelosuppression are rare but serious beenA started on azathioprine therapy for immunoglobulin (Ig) complications of azathioprine that are more likely to occur at G4-related biliary disease. Comorbidities included hypertension, high doses or when potentiated by interactions with other peripheral vascular disease, type 2 diabetes mellitus, salivary drugs. gland fibrosis, hypothyroidism, gastresophageal reflux disease, • Xanthine oxidase inhibitors such as allopurinol or febuxostat hyperlipidemia, osteoarthritis and gout. The patient was taking increase the production of myelotoxic metabolites from azathioprine. azathioprine 200 mg once daily and had been taking allopurinol 100 mg once daily for several years to manage his gout. Other • Initiation of azathioprine should be accompanied by regular monitoring of a complete blood count with differential and liver medications included sitagliptin 100 mg once daily, gliclazide enzymes at least every 2 weeks during initial dose titration, and, 120 mg once daily, acetylsalicylic acid 81 mg once daily, once stable, at least every 3 months thereafter, as clinically extended-release metoprolol 200 mg once daily, ramipril 5 mg appropriate. once daily, atorvastatin 40 mg once daily, rabeprazole 20 mg twice daily, clonazepam 2 mg at bedtime, gabapentin 100 mg 3 times daily, venlafaxine 225 mg daily, vitamin D 1000 IU once Investigations for anemia included upper and lower endos- daily and ibuprofen 800 mg as needed.
    [Show full text]
  • Guideline for Preoperative Medication Management
    Guideline: Preoperative Medication Management Guideline for Preoperative Medication Management Purpose of Guideline: To provide guidance to physicians, advanced practice providers (APPs), pharmacists, and nurses regarding medication management in the preoperative setting. Background: Appropriate perioperative medication management is essential to ensure positive surgical outcomes and prevent medication misadventures.1 Results from a prospective analysis of 1,025 patients admitted to a general surgical unit concluded that patients on at least one medication for a chronic disease are 2.7 times more likely to experience surgical complications compared with those not taking any medications. As the aging population requires more medication use and the availability of various nonprescription medications continues to increase, so does the risk of polypharmacy and the need for perioperative medication guidance.2 There are no well-designed trials to support evidence-based recommendations for perioperative medication management; however, general principles and best practice approaches are available. General considerations for perioperative medication management include a thorough medication history, understanding of the medication pharmacokinetics and potential for withdrawal symptoms, understanding the risks associated with the surgical procedure and the risks of medication discontinuation based on the intended indication. Clinical judgement must be exercised, especially if medication pharmacokinetics are not predictable or there are significant risks associated with inappropriate medication withdrawal (eg, tolerance) or continuation (eg, postsurgical infection).2 Clinical Assessment: Prior to instructing the patient on preoperative medication management, completion of a thorough medication history is recommended – including all information on prescription medications, over-the-counter medications, “as needed” medications, vitamins, supplements, and herbal medications. Allergies should also be verified and documented.
    [Show full text]
  • Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia with Cardiovascular Disease (TROFEO Trial)
    Circ J 2017; 81: 1707 – 1712 ORIGINAL ARTICLE doi: 10.1253/circj.CJ-17-0438 Preventive Medicine Cross-Over Trial of Febuxostat and Topiroxostat for Hyperuricemia With Cardiovascular Disease (TROFEO Trial) Akira Sezai, MD, PhD; Kazuaki Obata; Keisuke Abe; Sakie Kanno; Hisakuni Sekino, MD, PhD Background: We previously reported that febuxostat was more effective for hyperuricemia than allopurinol. The efficacy, however, of topiroxostat (a novel xanthine oxidase reductase inhibitor similar to febuxostat), for hyperuricemia is unknown. Methods and Results: Patients with cardiovascular disease and hyperuricemia, in whom serum uric acid (s-UA) was controlled at ≤6 mg/dL, were eligible for enrollment. Fifty-five patients were randomized to receive either febuxostat or topiroxostat for 6 months and were switched to the other drug for the following 6 months. The primary endpoint was s-UA. Secondary endpoints included serum creatinine, estimated glomerular filtration rate, urinary albumin, cystatin-C, oxidized low-density lipoprotein, eicosapentaenoic acid/ arachidonic acid ratio, lipid biomarkers, high-sensitivity C-reactive protein and B-type natriuretic protein. Although s-UA level was similar for both drugs, significantly more patients required dose escalation during treatment with topiroxostat. There were no differ- ences in renal function, inflammatory and lipid markers between the 2 drugs. A biomarker of oxidative stress was significantly lower after 3 months of febuxostat compared with topiroxostat. Conclusions: Febuxostat causes more marked and more rapid reduction of s-UA than topiroxostat. With regard to the antioxidant effect, febuxostat was superior to topiroxostat after 3 months. The renal protective and anti-inflammatory effects of both drugs were also similar after 6 months of treatment.
    [Show full text]
  • Febuxostat Ameliorates Methotrexate-Induced Lung Damage
    ONLINE FIRST This is a provisional PDF only. Copyedited and fully formatted version will be made available soon. ISSN: 0015-5659 e-ISSN: 1644-3284 Febuxostat ameliorates methotrexate-induced lung damage Authors: S. M. Zaki, G. H.A. Hussein, H. M.A. Khalil, W. A. Abd Algaleel DOI: 10.5603/FM.a2020.0075 Article type: ORIGINAL ARTICLES Submitted: 2020-06-17 Accepted: 2020-07-01 Published online: 2020-07-08 This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Folia Morphologica" are listed in PubMed. Powered by TCPDF (www.tcpdf.org) Febuxostat ameliorates methotrexate-induced lung damage Running title: Methotrexate-induced lung damage S.M. Zaki1, 2, G.HA. Hussein3, H.M.A. Khalil4, W.A. Abd Algaleel1 1Department of Anatomy and Embryology, Faculty of Medicine, Cairo University, Egypt 2Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia 3Department of Anatomy and Embryology, Faculty of Medicine, Beni Suef University, Egypt 4Department of Veterinary Hygiene and Management, Faculty of Veterinary Medicine, Cairo University, Egypt Address for correspondence: Sherif Mohamed Zaki, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia, e-mail: [email protected] Abstract Background: The intention of the present study was to study the structural affection of the lung following Methotrexate (MTX) overdose. The proposed underlying mechanisms involved in lung affection were studied. The possible modulation role of febuxostat over such affection was studied. Materials and methods: 24 rats were divided into three groups: control, MTX-treated, febuxostat-treated.
    [Show full text]
  • Report on the Deliberation Results May 8, 2013 Evaluation And
    Report on the Deliberation Results May 8, 2013 Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau Ministry of Health, Labour and Welfare [Brand name] (a) Topiloric Tablets 20 mg, 40 mg, and 60 mg (b) Uriadec Tablets 20 mg, 40 mg, and 60 mg [Non-proprietary name] Topiroxostat (JAN*) [Applicant] (a) Fujiyakuhin Co., Ltd. (b) Sanwa Kagaku Kenkyusho Co., Ltd. [Date of application] June 26, 2012 [Results of deliberation] In the meeting held on April 26, 2013, the First Committee on New Drugs concluded that the product may be approved and that this result should be presented to the Pharmaceutical Affairs Department of the Pharmaceutical Affairs and Food Sanitation Council. The product is not classified as a biological product or a specified biological product, the re-examination period is 8 years, and neither the drug substance nor the drug product is classified as a poisonous drug or a powerful drug. *Japanese Accepted Name (modified INN) This English version of the Japanese review report is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail. The PMDA will not be responsible for any consequence resulting from the use of this English version. Review Report April 15, 2013 Pharmaceuticals and Medical Devices Agency The results of a regulatory review conducted by the Pharmaceuticals and Medical Devices Agency on the following pharmaceutical product submitted for registration are as follows. [Brand name] (a) Topiloric Tablets 20 mg, 40 mg, and 60 mg (b) Uriadec Tablets 20 mg, 40 mg, and 60 mg [Non-proprietary name] Topiroxostat [Applicant] (a) Fujiyakuhin Co., Ltd.
    [Show full text]
  • ALLOPURINOL 300Mg TABLETS (Allopurinol)
    310 x180mm - side1 PACKAGE LEAFLET: INFORMATION FOR THE USER ALLOPURINOL 300mg TABLETS (Allopurinol) Read all of this leaflet carefully before you start taking this medicine. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. In this leaflet: 1. What Allopurinol Tablets are and what they are used for 2. Before you take Allopurinol Tablets 3. How to take Allopurinol Tablets 4. Possible side effects 5. How to store Allopurinol Tablets 6. Further information 1. WHAT ALLOPURINOL TABLETS ARE AND WHAT • Thiazide diuretics (certain fluid tablets) • Aspirin or related medicines (Salicylates) THEY ARE USED FOR • Probenecid (used in gout) The name of your medicine is Allopurinol 300mg Tablets. They • Chlorpropamide (used in diabetes) contain the active ingredient called Allopurinol, that belongs to a • Warfarin (used to help prevent blood clots) group of medicines called enzyme inhibitors, which act to control the • Phenytoin (used in epilepsy) speed at which chemical changes occur in the body. • Theophylline, used to treat asthma • Certain antibiotics like Amoxicillin and Ampicillin Allopurinol reduces the formation and accumulation of uric acid in the • Ciclosporin (used to treat psoriasis, rheumatoid arthritis or after body. They are used to prevent gout and gouty arthritis. These tablets organ transplants) should not be used to treat sudden attack of gout.
    [Show full text]